Evidence map›Paper›PMID 39853520›Full record

ArticleEuropean journal of pediatrics2025

Clinical, laboratory, and molecular characteristics of patients with spondyloenchondrodysplasia: a case series study.

Esra Pekpak Şahinoğlu, Ayse Ceyda Oren, Bahtiyar Şahinoğlu, Özlem Keskin, Çağrı Damar, Sinan Akbayram

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esra Pekpak ŞahinoğluPediatric Hematology and Oncology, Liv Hospital, Gaziantep, Turkey. mdesrapekpak@yahoo.com.ORCID http://orcid.org/0000-0003-2143-1435
Ayse Ceyda OrenPediatric Hematology and Oncology, Liv Hospital, Gaziantep, Turkey.ORCID http://orcid.org/0000-0002-7676-0095
Bahtiyar ŞahinoğluMedical Genetics, Gaziantep City Hospital, Gaziantep, Turkey.ORCID http://orcid.org/0000-0002-2208-540X
Özlem KeskinPediatric Immunology and Allergy, Gaziantep University School of Medicine, Gaziantep, Turkey.ORCID http://orcid.org/0000-0002-3061-7832
Çağrı DamarPediatric Radiology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0001-7208-1290
Sinan AkbayramPediatric Hematology and Oncology, Liv Hospital, Gaziantep, Turkey.ORCID http://orcid.org/0000-0001-7410-4310

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spondyloenchondrodysplasia (SPENCD) is a rare genetic disorder characterized with skeletal dysplasia, immune dysregulation, and neurological impairment. Patients diagnosed with SPENCD at a single pediatric hematology center were included in the study. The patients' clinical characteristics, symptoms at presentation, imaging and laboratory results, and genetic analysis results were collected retrospectively from their files. This study evaluated nine patients diagnosed with SPENCD, eight of whom had autoimmune manifestations at presentation. Common findings included autoimmune hemolytic anemia, hypothyroidism, and elevated transaminase levels. All patients exhibited short stature and skeletal abnormalities. Neurological symptoms were present in six patients, with intracranial calcifications detected in five. Recurrent bacterial and viral infections, including respiratory tract infections, were prevalent. The NM_001611.5 (ACP5): c.772_790del p.(Ser258TrpfsTer39) frameshift variant was identified in all patients. Two patients died during follow-up.

conclusionThe study highlights the clinical characteristics and challenges associated with SPENCD. The findings underscore the need for comprehensive management strategies to address the multifaceted complications associated with SPENCD. WHAT IS KNOWN: • Spondyloenchondrodysplasia (SPENCD) is classified as a type-1 interferonopathy resulting from homozygous mutations in the ACP5 gene, which leads to a deficiency in tartrate-resistant acid phosphatase. • The clinical features associated with this condition encompass skeletal dysplasia, spastic paraparesis, short stature, thrombocytopenia, hemolytic anemia, and systemic lupus erythematosus like autoimmune manifestations. Additionally, patients may experience intracranial calcifications and recurrent infections. WHAT IS NEW: • SPENCD exhibits similarities with other type I interferonopathies, including increased levels of type I interferon and specific neurological symptoms; however, it also displays distinct characteristics such as intellectual disability and behaviors associated with autism spectrum disorder. • Despite the rare occurence of the condition and the small number of patients reported here the findings underscore the complexity of managing this condition, particularly in the context of consanguinity and the associated risks of severe complications and mortality.

Indexed as

OsteochondrodysplasiasTartrate-Resistant Acid PhosphataseAdolescentAutoimmune DiseasesChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesACP5 protein, humanTartrate-Resistant Acid PhosphataseACP5ChildrenCytopeniaSpondyloenchondrodysplasia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.